Insights
citeline.com
As featured in
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Citeline is the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.
News
Emrelis and the Evolving Landscape of Antibody Drug Conjugates PharmExec
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, discusses how Emrelis fits into the current antibody-drug conjugate landscape and what distinguishes its approach in biomarker-driven oncology.
Read more
Report
Emrelis Approval Highlights FDA Confidence in ADC Oncology Treatments PharmExec
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis marks a pivotal moment for ADC therapies in oncology, reflecting the FDA's growing confidence in their safety and efficacy and accelerating the shift towa
Read more
Report
How Emrelis Is Expanding Treatment Options for Solid Tumors With C-MET Overexpression PharmExec
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, highlights Emrelis' potential to broaden its clinical impact by expanding into other solid tumors with high c-MET overexpression, beyond its current focus on non-small cell lung cancer.
Read more
Report
What the Emrelis Approval Means for Pharma and Biotech ADC Strategies PharmExec
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how the approval of Emrelis is accelerating investor interest, validating biomarker-driven ADCs, and shaping distinct strategic paths for pharma and biotech in the evolving precision
Read more
Report
Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment PharmExec
Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, expanding its presence in precision oncology and antibody-drug
Read more
Report
Pro access
Upgrade to see all 40 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.